Application of multilevel growth-curve analysis in cancer treatment toxicities: The exemplar of oral mucositis and pain by Dudley, William N. & NC DOCKS at The University of North Carolina at Greensboro
Application of multilevel growth-curve analysis in cancer treatment toxicities: the exemplar of oral 
mucositis and pain 
 
By: William N. Dudley, Deborah B. McGuire, Douglas E. Peterson and Bob Wong 
 
Dudley, W.N., McGuire, D.B., Peterson, D.E., & Wong, B. (2009). Application of multilevel growth-curve  
analysis in cancer treatment toxicities: The exemplar of oral mucositis and pain. Oncology Nursing 
Forum, 36(1), E11-E19. 
 
Made available courtesy of ONCOLOGY NURSING SOCIETY: http:/www.ons.org/Publications/ONF 
 
***Reprinted with permission. No further reproduction is authorized without written permission from 
the ONCOLOGY NURSING SOCIETY. This version of the document is not the version of record. 
Figures and/or pictures may be missing from this format of the document.*** 
 
Abstract: 
Purpose/Objectives: To introduce the use of a statistical technique known as multilevel growth-curve analysis 
and illustrate how the method can be advantageous in comparison with traditional repeated measures for the 
study of trajectories of signs and symptoms in individual patients over time.  
Data Sources: Data were derived from use of the technique in a randomized clinical trial of a 
psychoeducational intervention to reduce severity of oral mucositis and oral pain.  
Data Synthesis: The development of new biologic models that seek to explain clustering of signs and 
symptoms or the appearance and resolution of signs and symptoms motivates the need to use more sophisticated 
statistical techniques to test such models.  
Conclusions: The application of multilevel growth model to an existing data set demonstrates that the model 
can be effective in the study of individual differences in trajectories of change in signs and symptoms.  
Implications for Nursing: This method for the study of changes in patients' signs and symptoms over time can 
be of particular interest to nursing, both from a clinical point of view and as a way to test theoretical models that 
have been proposed to capture patient experiences with signs and symptoms. 
 
Article: 
The study of symptom clusters has become an important focus of oncology nursing research (Barsevick, 2007). 
Concurrently, longitudinal studies of clinical phenomena in which individuals are measured across time have 
become common. As the study of symptom clusters has matured, research has evolved beyond describing 
symptom clusters to questioning the underlying processes that lead to symptom clusters. These changes in 
research foci have led to biologic models of symptom clustering (Lee et al., 2004; Sonis, 2004a, 2004b) and a 
need for sophisticated statistical methods to test such models.  
Lee et al. (2004) proposed a general inflammatory model in which cancer therapies (chemotherapy or 
radiotherapy) lead to the release of cytokines that, in turn, generate specific clusters of symptoms in patients 
receiving treatment. In a model specific to oral mucositis (OM), Sonis (2004b) proposed a pathobiologic model 
of OM that models the development and resolution of that serious side effect of cancer therapy. Linkage of 
these models and related models represents an important development in symptom cluster research. Both of the 
biologic models propose a longitudinal chain of processes that underlie the clinical phenomena under study. For 
the science to progress, researchers must use statistical methods that can appropriately model individual 
trajectories of change, capture interindividual variability in change over time inherent in the models, and model 
factors that explain that variation.  
The traditional repeated-measures analysis of variance (ANOVA), which uses ordinary least-squares estimation, 
has long been the mainstay for statistical analyses of longitudinal clinical trials with continuous outcomes 
(Maxwell & Delaney, 2004). Repeated-measures ANOVA is highly effective in studying mean change and 
treatment group differences in mean change over a limited number of occasions with balanced data. However, it 
is less useful for the study of interindividual variability in trajectories of change that practitioners commonly see 
in clinical settings, specifically in the context of signs and symptoms related to cancer treatment. An alternative 
to traditional repeated-measures ANOVA is one of several growth-curve modeling approaches to examine 
interindividual variability in trajectories of change. One commonly used method is the multilevel growth model 
in which observations (sign or symptom severity) over time are "nested" within a patient. The patient's 
trajectories of change then are linked to patient-related characteristics (e.g., age, gender) or treatment-related 
characteristics (e.g., radiation dose) that can be thought of as correlates of change.  
The purpose of this article is to introduce growth-curve modeling of longitudinal data via the use of multilevel 
modeling and to illustrate the advantages of multilevel modeling with longitudinal clinical data over the 
traditional repeated-measures ANOVA model. It focuses on inter individual differences in trajectories of OM, a 
significant side effect of cancer therapy (Peterson, Keefe, Hutchins, & Schubert, 2006; Sonis et al., 2004).  
Oral Mucositis  
The current pathobiologic model of OM supports variations in clinical expression and is supported by 
substantial basic and clinical research (Sonis, 2002). Multilevel growth-curve models have the potential to 
integrate patient-based variations in clinical expression of OM within the pathobiologic model. Selected patient 
cohorts, including those receiving head and neck radiation (Elting, Cooksley, Chambers, & Garden, 2007) or 
hematopoietic stem cell transplantation (HSCT) (Sonis et al., 2004), typically demonstrate predictable peaks 
and troughs in severity of OM. However, distinct differences in the expression of signs and symptoms often 
occur across patients, even among those receiving similar treatment regimens, such as high-dose chemotherapy 
in preparation for stem cell transplantation. The variation may be seen in different trajectories of oral mucosal 
injury over time (the peaks and troughs noted previously) across individual patients. Such variation can include 
incidence and duration of clinically significant oral mucosal injury and can affect dose delivery of multi-cycle 
chemotherapy (Peterson, Jones, & Petit, 2007). In addition, the number of patients with solid tumors who 
experience OM is substantially higher than the number of patients undergoing head and neck radiation and 
HSCT combined (Avritscher, Cooksley, & Elting, 2004; Elting et al., 2003). In this model, clinical changes in 
oral tissue occur because of an underlying biologic process; also, individual trajectories of change are quite 
variable, and the variability may be the result of a host of patient-related (e.g., age, oral health) and treatment-
related (e.g., type of treatment regimen) factors. To test model-related hypotheses, a statistical model must 
quantify individual trajectories of change and correlate the trajectories to patient-related and treatment-related 
variables. It also must have the potential to relate changes in one sign or symptom to patterns of change in other 
signs or symptoms (as a researcher might do in a study of symptom clustering over time). The multilevel 
growth model discussed in this article is one statistical model that is consistent with those requirements.  
Multilevel Growth Models  
Multilevel Growth Models in the Study of Oral Mucositis  
A need exists for novel analytic approaches designed to integrate the modeling of OM among individual 
patients, vis-a-vis the collective patient experience, by quantifying individual trajectories of oral mucosal injury 
over time. As more and more researchers employ repeated-measure, longitudinal designs to study cancer signs 
and symptoms, the authors anticipate that the availability of longitudinal data will create a shift toward the use 
of new models for the study of change. The technique described in this article, multilevel growth-curve 
modeling, is one commonly used approach to the study of change over time.  
Multilevel growth-curve modeling also can contribute to an enhanced understanding of the OM experience 
within a constellation of signs and symptoms in patients undergoing high-dose cancer therapies. The concept of 
symptom clusters has emerged as an important paradigm in oncology (Barsevick, 2007; Dodd, Miaskowski, & 
Paul, 2001; Kim, McGuire, Tulman, & Barsevick, 2005; Lee et al., 2004; Miaskowski & Aouizerat, 2007). In 
that context, OM pathogenesis and clinical outcomes could be contributory to, or an outcome of, molecular-
based toxicities such as fatigue associated with tumor necrosis factor-[alpha], interleukin (IL)-6, IL-8, and 
epidermal growth factor (Lee et al.). The symptom clusters can exhibit considerable variation across patients 
with cancer, even among those receiving comparable treatment regimens. Multilevel growth-curve modeling 
may help to elucidate and integrate data on OM with data related to the collective symptom experience across 
patients.  
Statistical Basis  
The methods presented herein are based on the seminal work by Bryk and Raudenbush (1992) and subsequent 
work of numerous methodologists (Curran, 2000; Singer & Willett, 2003; Verbeke & Molenberghs, 2000). A 
number of approaches to growth-curve modeling exist. Multilevel growth-curve modeling is used commonly 
because it is generalizable to other approaches, such as individual growth-curve modeling or latent curve 
growth-curve modeling. The approaches share a common statistical model discussed in detail later.  
As the name suggests, a multilevel model consists of a number of hierarchically nested regression models in 
which model parameters (i.e., regression coefficients, standard errors, variance components, and covariance 
components) are computed simultaneously. Typical longitudinal multilevel modeling involves two different 
levels of equations: level 1 and level 2. The level 1 equations capture within-subject variability, in this case 
individual change over time, whereas level 2 equations capture between-subject variability. The authors 
describe both levels of equations in the following sections. After the authors present the statistical model, they 
discuss how the statistical model relates to the symptom experience over time in a sample of patients.  
Level 1 equations: In the level 1 equation, each individual subject's change over time is a separate regression 
equation. In other words, each subject's outcome on the dependent variable(s) (erythema and pain in this 
example) is regressed onto the variable of time of measurement (e.g., day 1, day 2, day 3). The result is a 
regression equation (which may be linear or nonlinear) that represents each individual subject's growth curve. 
The coefficients that make up the regression equation are the individual subject's growth-curve parameters. 
With standard Cartesian coordinates, the Y intercept is the value in the outcome variable where the growth 
curve (either individual or group mean) intersects the abscissa axis (typically at a baseline day = 0). The linear 
rate of growth is termed slope, which is the amount of change in the dependent variable per unit of time. A 
quadratic term describes the amount of acceleration or deceleration (nonlinear increase or decrease) of the same 
dependent variable per unit of time squared.  
Equation 1 is the general level 1 regression equation that captures individual change over time in some outcome 
(in this case, the authors used erythema to illustrate the process). Unlike repeated-measures ANOVA, which 
aggregates information and loses individual differences, multilevel models retain individual information and 
develop separate regression equations for each subject. The subscript "i" indicates an individual. The subscript 
"t" indicates time, which could be actual days from a baseline zero or, as more commonly encountered in 
clinical research, an ordinal series of time (e.g., first treatment, second treatment).  
Equation 1: [Y.sub.ti] = [[pi].sub.0i] + [[pi].sub.1i] [[alpha].sub.ti] + [[pi].sub.2i] [[alpha].sub.ti.sup.2] + 
[[epsilon].sub.ti]  
From equation 1, [Y.sub.ti] is subject i's erythema score at measurement t; [a.sub.ti] is the day of measurement 
postchemotherapy (e.g., 0, 1, 2, 3) for the erythema score and represents linear change. The 
[[alpha].sub.ti.sup.2] term is the time of measurement squared and represents curvilinear change over time. 
[[epsilon].sub.ti] is the difference between the observed erythema score at time t for subject i ([Y.sub.ti]) and 
the predicted erythema score. [[epsilon].sub.ti] is a residual value that indicates an individual subject's 
variability. Because the authors must estimate a separate level 1 equation for each subject, the timing of 
measurement occasions and the number of measurement occasions may vary over subjects. Thus, multilevel 
models can handle unbalanced designs as opposed to traditional repeated-measures ANOVA. Unbalanced 
designs refer to data collection processes in which the number of measurement occasions differs from one 
patient to another. The discrepancy may be a result of missing data or duration of treatment regimen conditions 
that often are encountered in longitudinal clinical studies. The ability to handle varying times of measurement 
and number of measurement occasions is critical in the longitudinal study of clinical phenomena.  
Each subject's level 1 equation, called a growth curve, consists of a function of growth parameters: a Y 
intercept, [[pi].sub.0i]; a slope, [[pi].sub.1i]; a quadratic term, [[pi].sub.2i]; and an error term, [[epsilon].sub.ti]. 
The Y intercept, [[pi].sub.0i], is an individual subject i's predicted erythema score where time is zero (i.e., 
[a.sub.ti] = 0). Y intercepts are estimated and interpreted where the other variables in the equation are set to zero 
(Biesanz, Deeb-Sossa, Papadakis, Bollen, & Curran, 2004; Cohen, Cohen, West, & Aiken, 2003; Wainer, 
2000). The linear change rate, or slope of the growth curve for individual subject i, is [[pi].sub.1i]. The slope is 
the predicted linear rate of change in erythema scores per unit of time, t. In the quadratic model, the slope has a 
special meaning. It is the rate of change at the intercept. That is, it is the slope of the line passing through the 
intercept and tangent to the curve represented by the quadratic term (Singer & Willett, 2003). The quadratic 
growth parameter for subject i is [[pi].sub.2i], and it is the rate of acceleration (or deceleration if negative) in 
erythema scores per unit of time squared, [t.sup.2].  
 
 
To illustrate the Y intercept and slope concepts, Figure 1 shows a linear growth curve fitted to a hypothetical 
subject's erythema scores for the first four time points (day 0, day 1, day 2, and day 3) using the equation 
described earlier. For simplification purposes, the figure does not show the quadratic term. The circles represent 
the measured erythema score at days t = 0, 1, 2, and 3, and the dotted line is the subject's growth curve. The Y 
intercept, [[pi].sub.0i]; slope, [[pi].sub.1i]; and residuals, [[epsilon].sub.ti], for the subject's growth curve are 
labeled.  
Level 2 equations: Estimation of the growth parameters (i.e., intercept, slope, and quadratic term) in level 1 
equations involves a different set of regression equations. Each growth parameter is modeled by a regression 
equation that captures the population main effect plus the variability resulting from each individual. The level 2 
equations for the current example consist of three regression equations. As shown here, equation 2 examines 
subjects' intercept values, equation 3 estimates subjects' linear slope parameter values, and equation 4 estimates 
subjects' quadratic parameter values.  
Equation 2: [[pi].sub.0l] = [[beta].sub.00] + [[mu].sub.0l]  
Equation 3: [[pi].sub.1l] = [[beta].sub.10] + [[mu].sub.1l]  
Equation 4: [[pi].sub.2l] = [[beta].sub.20] + [[mu].sub.2l]  
Recalling equation 1,  
[Y.sub.ti] = [[pi].sub.0l] + [[pi].sub.1l] [[alpha].sub.tl] + [[pi].sub.0l] [[alpha].sub.tl.sup.2] + [[epsilon].sub.tl]  
the authors substitute the [beta]s and [mu]'s for the growth parameters to yield equation 5.  
[Y.sub.ti] = ([[beta].sub.00] + [[mu].sub.0l]) + ([[beta].sub.10] + [[mu].sub.1l])[[alpha].sub.tl] + ([[beta].sub.20] 
+ [[mu].sub.2l]) + [[epsilon].sub.tl]  
Figure 2 shows a hypothetical grand mean linear growth curve shown as a solid line with the individual 
subject's growth curve shown as a dashed line. The coefficients of the level 2 equations are labeled.  
Figure 2 illustrates the relationship between the individual's trajectory of erythema and the mean (across all 
individuals) trajectory of erythema. In the figure, the dashed line is identical to the line portrayed in Figure 1. 
The solid line in Figure 2 portrays the mean trajectory, and the parameters of interest include the parameters for 
the mean trajectory (the [beta] terms) as well as the parameters for the deviation of the individual from the mean 
(the [mu] terms). The parameters are described in the following sections.  
[beta]-terms fixed effects: Three [beta] terms exist: [[beta].sub.00], [[beta].sub.10], and [[beta].sub.20]. In 
repeated-measures ANOVA terminology, the terms represent population main effects. In growth-modeling 
terminology, [[beta].sub.00] is the grand mean intercept. The interpretation of this mean intercept for growth 
modeling is different from repeated-measures ANOVA, which interprets the intercept as the value aggregated 
across all subjects and all time points. Therefore, it is the average value of erythema regardless of time. For 
growth modeling, the intercept typically is set to represent the initial or beginning value of the dependent 
variable at time 0 ([[alpha].sub.ti] = 0). The statistical testing of [[beta].sub.00] determines whether the intercept 
value differs from zero. Other interpretations of the intercept can be accomplished by centering the data on a 
time point that is not zero. For example, if the time variable was centered on the mean time value, in the current 
example 1.5 days ([[alpha].sub.ti] = 1.5), then the intercept would be consistent with the repeated-measures 
ANOVA results, because the mean intercept value would be calculated at the mean time value. [[beta].sub.10] 
is the grand mean slope, or average linear rate of change per unit of time for the population growth curve. 
Testing [[beta].sub.10] against zero is similar to orthogonal linear contrasts in repeatedmeasures ANOVA 
terminology (Biesanz et al., 2004). [[beta].sub.20] is the grand mean quadratic term, or average change in slope 
value per squared unit of time.  
[mu]-terms random effects: Figure 2 illustrates two random coefficients: [[mu].sub.0i] is the random coefficient 
for the intercept, whereas [[mu].sub.1i] is the random coefficient for slope. The term [[mu].sub.0i] is the 
difference between the individual's Y intercept ([[pi].sub.0i]) and the overall grand mean intercept 
([[beta].sub.10]), whereas the term [u.sub.1i] is the deviation between the individual's slope and the overall 
grand mean slope ([[beta].sub.10]). Referring to Figure 2, the individual's Y intercept is higher than the grand 
mean intercept, whereas the individual's slope is shallower than the grand mean slope.  
Each individual has his or her own random coefficient [[mu].sub.0i] and [[mu].sub.1i] terms. The statistical 
testing of the variability of the terms is the key difference between multilevel modeling and traditional repeated-
measures ANOVA. If statistically significant variability exists in any of the growth parameters (intercepts, 
slopes, and quadratic terms), a researcher can add predictor variables to the level 2 equations to explain the 
variability. The ability to use patient-level predictor variables allows multilevel models to explore individual 
differences.  
 
 
Using Raudenbush amd Bryk's (2002) terminology, a model that describes the variability among growth 
parameters without predictor variables is called an unconditional model. An unconditional model that adds 
predictor variables to explain any significant variance in growth parameters is called a conditional model. The 
authors present a numerical example of unconditional and conditional growth modeling in the next section.  
Relationship of the Statistical Model to Clinical Phenomena  
The model discussed earlier is a representation of how a sample of patients might change over time with regard 
to a single sign or symptom. The level 1 model captures the process of change in an individual. What clinicians 
might see as an absence of a sign or symptom at the start of therapy followed by a rapid development and 
resolution of erythema for a given patient would be captured as growth parameters for that patient. The 
parameters would indicate an intercept of zero and a quadratic term that is highly negative (the slope term is 
less important in a quadratic model than in a linear model). Just as each patient might show a different pattern 
of rise and fall of erythema, the level 1 parameters (the Y intercept, [[pi].sub.0i]; slope, [[pi].sub.1i]; and 
quadratic term, [[pi].sub.2i]) would differ. In addition, if the clinical phenomena were known to show a variable 
expression, a researcher would expect that the measures on individual variability in the statistical model (the 
[mu] terms discussed earlier) would show a high degree of variability. Finally, just as a clinician might see that 
the progression of erythema could differ depending on gender or previous history, the conditional model 
discussed earlier could test that association. In those ways, the statistical model can be congruent with the 
clinical picture and can serve as a rigorous test of hypotheses that are developed from clinician experiences or 
from a biologic model such as that proposed by Sonis (2004a). Thus, with an appreciation of the fundamentals 
of growth-curve modeling, researchers can formulate questions about changes in signs or symptoms in a more 
rigorous fashion and develop hypotheses that can be subjected to statistical analyses.  
Example of Growth-Curve Modeling Using Oral Mucositis and Pain Data  
Parent Study  
To illustrate the growth-curve modeling approach to studying change over time, the authors employed 
individual growth-curve modeling to clinicians' observational ratings of erythema and patients' self-reported 
ratings of oral pain, the defining components of OM (McGuire et al., 1993). In the parent study (McGuire, 
Yeager, et al., 1998), a sample of 153 patients received high-dose chemotherapy in preparation for bone marrow 
or stem cell transplantation (n = 133) or for leukemia induction therapy (n = 20). Although the study was a 
randomized clinical trial testing the effects of a psychoeducational intervention for reducing duration and 
severity of OM and pain, data from the experimental and usual control groups were aggregated for the purposes 
of this analysis. After patients completed chemotherapy, researchers collected data from patients in their 
hospital rooms on designated study days (three times per week) in a manner designed to capture developing, 
peaking, and resolving OM and pain. Trained nurses and a dentist conducted observational ratings of OM 
(including erythema) using the 20-item Oral Mucositis Index (McGuire et al., 2002). Patients self-reported 
ratings of oral pain using the Brief Pain Inventory (Cleeland, 1989). The erythema score was computed as the 
mean of severity of erythema (rated on a scale ranging from 0 [normal] to 3 [severe] across nine sites in the 
mouth [upper and lower labial mucosa; right and left buccal mucosa; dorsal, lateral, and ventral tongue; floor of 
the mouth; and soft palate]). Erythema and oral pain scores were similar to total average scores reported in 
earlier studies (McGuire et al., 1993; Schubert, Williams, Lloid, Donaldson, & Chapko, 1992). The focus here 
is on erythema as opposed to ulceration because ulceration was less prominent than erythema in the parent 
study data.  
Modeling  
The unconditional and conditional growth-curve models were estimated, as recommended by Byrk, 
Raudenbush, and Congdon (2002). In the process, the researchers estimated a quadratic form of the trajectories 
of erythema over eight time points that were defined as study days. The quadratic form was chosen because 
previous reports of OM have indicated this type of trajectory (McGuire et al., 1993; Sonis, 2004a; Woo, Sonis, 
Monopoli, & Sonis, 1993). Models were conducted with no centering, so the intercept is equivalent to the level 
of erythema and pain at the beginning of the study, the linear slope indicates the rate of change per unit of time, 
and the quadratic term indicates the curvature (acceleration or deceleration) of erythema and pain scores.  
The first analysis conducted was an unconditional model to inferentially test that the intercept, slope, and 
quadratic terms were different from zero and to investigate whether the individual differences in the growth 
parameters had sufficient variability. The second analysis consisted of adding the predictor variable of gender to 
explain residual variance (variability), thus creating a conditional model. The models' equations with intercept, 
linear, and quadratic parameters for erythema are shown next. Parameter estimates for both erythema and self-
reported OM pain are shown in Table 1.  
 
Table 1. Results for Unconditional and Conditional Growth Models of 
Erythema 
  
                    Unconditional Model  Conditional Model 
  
Fixed Effect          Estimate     SE      Estimate     SE 
  
[[beta].sub.00] =    0.0313      0.0275   0.0322      0.0276 
intercept 
  
[[beta].sub.10] =    0.0433 ***  0.0122   0.1158 ***  0.0151 
slope 
  
[[beta].sub.20] =   -0.0065 ***  0.0006  -0.0052 ***  0.0007 
quadratic 
  
[[beta].sub.11] =       --         --     0.0638 **   0.0215 
gender (slope) 
  
[[beta].sub.21] =       --         --    -0.0030 **   0.0010 
gender (quadratic) 
  
Random Effect       Variance Component   Variance Component 
  
[[mu].sub.1i]         [[tau].sub.11] =     [[tau].sub.11] = 
                         0.0150 ***           0.0141 *** 
  
[[mu].sub.21]         [[tau].sub.22] =     [[tau].sub.22] = 
                         0.0000 ***           0.0000 *** 
  
[[epsilon].sub.ti]   [[sigma].sup.2] =    [[sigma].sup.2] = 
                         = 0.1678              = 0.1682 
  
* p < 0.05; ** p < 0.01; *** p < 0.001 
  
SE--standard error 
Level 1: [Y.sub.ti] = [[pi].sub.0l] + [[pi].sub.1l] [[alpha].sub.tl] + [[pi].sub.2l] [[alpha].sub.tl.sup.2] + 
[[epsilon].sub.tl]  
Level 2: [[pi].sub.0l] = [[beta].sub.00] + [[mu].sub.0i]  
[[pi].sub.1l] = [[beta].sub.10] + [[mu].sub.1l]  
[[pi].sub.2l] = [[beta].sub.20] + [[mu].sub.2l]  
Unconditional model results: The model for erythema demonstrated no centering of data, which allowed 
[[beta].sub.00] to represent the mean intercept at the beginning of the study. The estimate [[beta].sub.00] = 
0.0313 was not statistically significant from zero (i.e., patients began the study with no erythema on average). 
[[beta].sub.01] was the mean linear rate across time, and the estimate [[beta].sub.00] = 0.1433 was statistically 
significant from zero, indicating an increase in erythema at the outset of the study. The estimate [[beta].sub.20] 
= -0.0065 was negative and differed significantly from zero, indicating that, on average, subjects' erythema first 
rose and then declined (recall that the quadratic term is a nonlinear change, which can be seen by the downward 
curvature of erythema scores in Figure 3). Similar results were obtained with unconditional modeling of self-
reported OM pain over time (see Table 2). Thus, in erythema and oral pain, the overall process of change was 
similar, the intercept was zero, severity increased at the start of the study, and resolution (or partial resolution) 
occurred as the study progressed.  
 
Table 2. Results for Unconditional and Conditional Growth Models of 
Self-Reported Oral Pain From Mucositis 
  
                    Unconditional Model   Conditional Model 
  
Fixed Effect         Estimate      SE      Estimate     SE 
  
[[beta].sub.00] =    0.0570      0.0984   0.0586      0.0985 
intercept 
  
[[beta].sub.10] =    0.4193 ***  0.0400   0.6993 ***  0.1165 
slope 
  
[[beta].sub.20] =   -0.0206 ***  0.0020  -0.0349 ***  0.0059 
quadratic 
  
[[beta].sub.11] =      --          --    -0.1780 *    0.0696 
gender (slope) 
  
[[beta].sub.21] =      --          --     0.0091 *    0.0036 
gender (quadratic) 
  
Random Effect       Variance Component   Variance Component 
  
[[mu].sub.1i]        [[tau].sub.11] =      [[tau].sub.11] = 
                        0.1471 ***            0.1403 *** 
  
[[mu].sub.21]        [[tau].sub.22] =      [[tau].sub.22] = 
                        0.0003 ***            0.0003 *** 
  
[[epsilon].sub.ti]  [[sigma].sup.2] =     [[sigma].sup.2] = 
                        = 2.1893              = 2.1933 
  
* p < 0.05; ** p < 0.01; *** p < 0.001 
  
SE--standard error 
 
 
Investigation of the variance components among subjects' linear slope and quadratic random effects (i.e., 
[T.sub.11] and [T.sub.22]) revealed that both the linear slope and quadratic random effects differed significantly 
from zero, indicating variability in linear growth rates and quadratic effects among subjects that may be 
accounted for by additional predictor variables. The nonsignificant random effect of intercept indicates no 
variability in initial levels of erythema that could be accounted for by predictor variables. Thus, the random 
effect for intercept was dropped from the unconditional and conditional model. Explaining the significant 
variance among subjects' growth parameters (e.g., linear slope, quadratic effect) demonstrates how growth 
modeling better represents individual differences in forms of change over time compared to repeated-measures 
ANOVA approaches.  
Conditional model results: By adding the predictor variable of gender to the unconditional model for erythema 
and pain, the researchers obtained the following equations.  
Level 1: [Y.sub.ti] = [[pi].sub.0l] + [[pi].sub.1l] [[alpha].sub.tl] + [[pi].sub.2l] ([[alpha].sub.tl.sup.2]) + 
[[epsilon].sub.tl]  
Level 2: [[pi].sub.0l] = [[beta].sub.00]  
[[pi].sub.1l] = [[beta].sub.10] + [[beta].sub.11] (gender) + [[mu].sub.1l]  
[[pi].sub.2l] = [[beta].sub.20] + [[beta].sub.21] (gender) + [[mu].sub.2l]  
 
 
For the conditional model, gender was coded as female = 0 and male = 1. Like the unconditional model, no 
centering of data occurred, which allowed [[beta].sub.00] to represent the mean intercept at the beginning of the 
study. Investigation of the conditional erythema model indicated that, similar to the unconditional model for 
erythema, the estimate [[beta].sub.00] = 0.0322 was not statistically significantly different from zero. 
Interpreting the other growth parameters requires some care. [[beta].sub.10] was the mean linear rate across 
time when gender = 0 (i.e., female), and the estimate [[beta].sub.01] = 0.1158 was statistically significantly 
different from zero. The estimate [[beta].sub.20] = -0.0052 was the average curvature when gender = 0 (female) 
and was significantly different from zero. [[beta].sub.11] = 0.0638 was the additional linear slope when gender 
= 1 (male) and was significantly different from zero. The additional linear slope effect for being male is 
illustrated in Figure 4, where the males show a faster rise in erythema severity than females. The estimate 
[[beta].sub.21] = -0.0030 was the additional quadratic estimate when gender = 1 (male) and was significantly 
different from zero. The additional quadratic effect for being male also is illustrated in Figure 3, where the 
males show a sharper decline in erythema severity past the zenith (i.e., more curvature). Investigation of the 
variance components among subjects' linear slope and quadratic random effects (i.e., [[tau].sub.11] and 
[[tau].sub.22]) revealed that both the linear slope and quadratic random effects differed significantly from zero, 
indicating variability in linear growth rates and quadratic effects among subjects that may be accounted for by 
additional predictor variables besides gender. Self-reported ratings of oral pain showed very similar results; the 
growth parameters are included in Table 2.  
 
Discussion  
This article delineates the utility of multilevel growth-curve modeling to the study of change over time. The 
authors demonstrated that utility by the application of multilevel models to repeated measures of OM (clinician-
rated erythema and patient self-reported ratings of oral pain). The results for erythema and pain were consistent 
with previous reports in the literature (McGuire et al., 1993; Schubert et al., 1992; Sonis, 2004b; Woo et al., 
1993). The quadratic models of change also resulted in significant models commensurate with published reports 
of patterns of OM based on typical mean scores (McGuire et al., 1993; Schubert et al.; Sonis, 2004b; Woo et 
al.). In addition, the curve parameters of erythema were associated with gender, which also is consistent with 
reports of factors associated with OM (Avritscher et al., 2004). Another important outcome of the analyses is 
that the results help support or extend understanding of the pathobiologic model of OM (Sonis, 1998, 2004b), 
including clinical manifestations, correlates, and risk factors.  
This article is the first report, to the authors' knowledge, to examine the utility of multilevel growth-curve 
analysis in studying changes in OM over a clinical trajectory. Future studies could employ similar methods to 
test predictions based on the evolving pathobiologic model of OM (Anthony, Bowen, Garden, Hewson, & 
Sonis, 2006; Sonis, 2007; Sonis et al., 2007; Sonis, 1998, 2004b), with the aim of adding to existing knowledge 
about this critically important side effect of high-dose chemotherapy. For example, multilevel growth-curve 
analysis might be used to predict whether individual trajectories of change in erythema and ulceration are 
related to patient-related (e.g., demographic) or treatment-related (e.g., diagnosis, treatment regimen) variables 
or to underlying mechanistic processes indicated by biologic measures such as cytokine levels. Thus, this 
analytic strategy could contribute to an enhanced understanding of pathobiologically based individual variations 
in the clinical expression of OM.  
 
Another critical advantage of using multilevel growth-curve analysis is that analyses could lead to fuller 
integration of mechanistic and etiologic models such as Sonis' (2004a) OM model into the broader context of 
symptom clusters in patients with cancer (Barsevick, 2007; Kim et al., 2005; Lee et al., 2004; Miaskowski & 
Aouizerat, 2007). For example, the pathobiologic model of mucositis suggests that the complex processes 
underlying the development of OM also may be implicated in the development of other signs and symptoms 
that are observed concurrently with mucositis, such as pain, sleeping alterations, fatigue, and emotional distress 
(Gaston-Johansson, Fall-Dickson, Bakos, & Kennedy, 1999; Lee et al.; McGuire, 2002; McGuire et al., 1993; 
McGuire, Owen, & Peterson, 1998; Miaskowski & Aouizerat). With increased knowledge of underlying 
causative mechanisms and new ways to analyze change over time in multiple signs or symptoms, the 
interrelationships of pathobiology and clinical trajectories may be explored in ways that advance understanding 
of symptom clusters more rapidly.  
Another potential use of this methodology is in the analysis of other symptoms (e.g., fatigue) or combinations of 
signs and symptoms (e.g., OM, pain, fatigue). It could be an important new approach to analyzing potentially 
complex relationships among symptoms in patients with cancer. Finally, this method offers useful advantages 
for current and future work on uncovering processes that underlie the clustering of symptoms, consistent with 
recommendations by numerous experts (Barsevick, 2007; Barsevick, Whitmer, Nail, Beck, & Dudley, 2006; 
Kim et al., 2005; National Institutes of Health, 2002). Relevant targets could include proposed models for 
relationships among symptoms such as Lee et al.'s (2004) cytokine model and Parker, Kimble, Dunbar, and 
Clark's (2005) symptom interactional framework.  
Limitations  
As with any research, the results presented herein have some inherent limitations. First, they reflect a secondary 
data analysis from a study testing the effects of a psychoeducational intervention in reducing the duration and 
severity of OM and oral pain in patients receiving high-dose chemotherapy, so the data were analyzed for 
different purposes than intended in the original study. Second, considerable data were missing beginning at 
about 14 days after initiation of chemotherapy because of patient discharges from the hospital, which limited 
the researchers' ability to apply the growth-curve techniques across the full trajectory of signs and symptoms. 
Substantive studies may require the use of sensitivity analyses to control for biases resulting from data that are 
not missing at random (Diggle & Kenward, 1994; Troxel, Harrington, & Lipsitz, 1998).  
Conclusion  
This article illustrates the potential utility of multilevel growth-curve modeling techniques in the study of 
change in signs and symptoms over time. The results relative to the analysis of erythema are consistent with 
previously published studies and extend the modeling by delineating several patterns obscured by traditional 
analyses of mean scores. Knowledge of these patterns may help clinicians approach assessment differentially, 
depending on treatment and other factors. The multilevel growth-curve modeling technique appears to be well 
suited to complex modeling of multiple signs or symptoms and related outcomes. The method may enhance the 
ability of researchers to analyze results of the complex data that emerge when symptom clusters are being 
studied. The data include the process of change in clinical signs and symptoms and the relationship of such 
processes to other individual and clinical characteristics of patients, as well as to underlying mechanistic 
models.  
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